Biocon has announced that its Board has approved the appointment of Peter Bains as the Group Chief Executive Officer (CEO), with effect from September 18th, 2023. He will be reporting directly to Biocon Group Chairperson, Kiran Mazumdar-Shaw.

Bains has accordingly stepped down from his role on the Biocon Board as an Independent Director with immediate effect, to assume this strategic executive responsibility.

He has a unique fit and profile for the role having both extensive global leadership experience and success across the biopharmaceutical field and a comprehensive understanding of the Biocon Group, having led Syngene for 5 years, taking it through its very successful IPO in 2015.

Siddharth Mittal, CEO & MD Biocon; Shreehas Tambe, CEO & MD Biocon Biologics; and Jonathan Hunt, CEO & MD  Syngene International will continue to have independent charge of their businesses and will work with Bains to strengthen synergistic strategic leadership at a Group level to maximise the combined value of all 3 businesses.